GFAP and neoplasm: The tumor was strongly immuno-reactive for GFAP (Figure 3B), SMARCB/INI-1 was preserved, and the tumor was negative for chromogranin, synaptophysin, Cam 5.2, EMA, desmin, myogenin, neurofilament and mutant-specific IDH1 (R132H).